Last reviewed 2026-04-22 · How we verify

Quinvaxem/Tritanrix

Quinvaxem/Tritanrix is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b.

Quinvaxem/Tritanrix is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b. Used for Primary immunization against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b in infants and children.

At a glance

Mechanism of action

This pentavalent vaccine contains inactivated toxoids (diphtheria and tetanus), acellular pertussis antigens, recombinant hepatitis B surface antigen, and polyribosylribitol phosphate conjugate from Haemophilus influenzae type b. Upon administration, these antigens trigger both humoral and cellular immune responses, leading to the production of protective antibodies and memory cells against these five pathogens.

Approved indications

• Primary immunization against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b in infants and children

Common side effects

• Injection site reactions (pain, redness, swelling)
• Fever
• Irritability
• Drowsiness
• Loss of appetite

Key clinical trials

• Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood Vaccination (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Quinvaxem/Tritanrix CI brief — competitive landscape report
• Quinvaxem/Tritanrix updates RSS · CI watch RSS
• Crucell Holland BV portfolio CI